CD8A and melanoma: Encapsulation with adjuvants (TLR1/2 ligand, Pam3CSK4; poly[I:C], polyinosinic:polycytidylic acid) and antigen (HPV-E7) into biodegradable poly(lactic-co-glycolic acid) NPs (PGLAαCD40-mAb) enabled selective DC delivery and effective B16-OVA melanoma tumor killing, with HPV-E7-specific CD8+ T cell immune response [241].